← Back to Clinical Trials
Recruiting NCT06749405

NCT06749405 Assessment of a Quantra-guided Transfusion Algorithm in Liver Transplantation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06749405
Status Recruiting
Phase
Sponsor University Hospital, Toulouse
Condition Liver Transplantation
Study Type INTERVENTIONAL
Enrollment 56 participants
Start Date 2025-03-08
Primary Completion 2027-03

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Transfusion algorithm based on Quantra®Conventional transfusion algorithm

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 56 participants in total. It began in 2025-03-08 with a primary completion date of 2027-03.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Liver transplantation carries a substantial risk of bleeding, making precise haemostasis control essential, although assessing coagulation remains challenging. Quantra, a bedside viscoelastic testing device using sonorheometric methods, offers an innovative approach to guiding haemostatic management during surgery. The study aims to determine whether a Quantra-guided transfusion can reduce transfusion and bleeding during liver transplantation when compared to a conventional transfusion approach.

Eligibility Criteria

Inclusion Criteria: * Patients aged 18 years or older * Patient with ESLD undergoing liver transplantation * Individuals affiliated with or beneficiaries of a social security scheme * Free and informed written consent obtained in writing from the patient, or where applicable from the trusted person/family member/close relative Non-inclusion Criteria: * Multi-organ transplantation * Congenital haemostasis disorder (such as haemophilia) * Patient under juridical protection (persons deprived of liberty or under curatorship or guardianship or safeguard of justice) * Pregnant or breast-feeding woman * Patient already enrolled in another interventional study with primary or secondary objective of reducing perioperative bleeding or transfusion

Contact & Investigator

Central Contact

Guillaume PORTA BONETE, Md

✉ porta-bonete.g@chu-toulouse.fr

📞 561323565

Principal Investigator

Guillaume PORTA BONETE, Md

PRINCIPAL INVESTIGATOR

University Hospital, Toulouse

Frequently Asked Questions

Who can join the NCT06749405 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Liver Transplantation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06749405 currently recruiting?

Yes, NCT06749405 is actively recruiting participants. Contact the research team at porta-bonete.g@chu-toulouse.fr for enrollment information.

Where is the NCT06749405 trial being conducted?

This trial is being conducted at Toulouse, France.

Who is sponsoring the NCT06749405 clinical trial?

NCT06749405 is sponsored by University Hospital, Toulouse. The principal investigator is Guillaume PORTA BONETE, Md at University Hospital, Toulouse. The trial plans to enroll 56 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology